## **Core Concept**
Doxorubicin, also known as Adriamycin, is an anthracycline antibiotic that is widely used in chemotherapy for various types of cancer. Its mechanism of action involves intercalating DNA strands, thereby inhibiting the synthesis of macromolecules and inducing apoptosis in cancer cells. However, this action is not specific to cancer cells, leading to significant toxicity.

## **Why the Correct Answer is Right**
The primary toxicity of doxorubicin is **cardiotoxicity**. This cardiotoxicity can manifest as acute, subacute, or chronic. The chronic form is dose-dependent and can lead to congestive heart failure. The mechanism behind doxorubicin's cardiotoxicity involves the generation of free radicals, which damage cardiac myocytes, and the drug's ability to bind to iron, forming complexes that catalyze the formation of hydroxyl radicals, leading to cellular damage.

## **Why Each Wrong Option is Incorrect**
- **Option A:** While doxorubicin can cause myelosuppression leading to **leukopenia**, **thrombocytopenia**, and **anemia**, this is not its primary toxicity. Myelosuppression is a common side effect of many chemotherapeutic agents.
- **Option B:** **Nephrotoxicity** is not the primary toxicity associated with doxorubicin. Though some chemotherapeutic agents can cause kidney damage, doxorubicin's main concern is not nephrotoxicity.
- **Option C:** **Hepatotoxicity** can occur with various drugs, including some chemotherapeutic agents. However, it is not the primary toxicity of doxorubicin.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl regarding doxorubicin is that its cardiotoxicity can be reduced by using **dexrazoxane**, a cardioprotective agent that chelates iron and prevents the formation of free radicals. Additionally, monitoring the patient's left ventricular ejection fraction (LVEF) before and during treatment can help in early detection of cardiotoxicity.

## **Correct Answer:** . Cardiotoxicity